Christopher Willett, MD, of Duke Cancer Center, discusses short and long courses of treatment, neoadjuvant chemotherapy with or without radiation, and organ preservation without surgery.
Daniel T. Chang, MD, of the Stanford Cancer Institute, discusses the role of radiation therapy in the treatment of hepatocellular carcinoma.
Kenneth Anderson, MD, of Dana-Farber Cancer Institute, discusses how the many advances in the treatment of multiple myeloma affect current and future clinical practice.
Anne Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the role of ablation and arterial-directed therapy in the treatment of hepatocellular carcinoma.
Joseph V. Simone, MD, of the Simone Consulting Company, gives his expert perspective on the important messages of this year’s meeting.
Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
